(VIANEWS) – The NASDAQ ended the session with Novavax (NVAX) rising 9.02% to $5.84 on Friday while NASDAQ jumped 0.19% to $14,761.56.
Novavax’s last close was $5.36, 71.11% under its 52-week high of $18.55.
About Novavax
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Earnings Per Share
As for profitability, Novavax has a trailing twelve months EPS of $-6.23.
Sales Growth
Novavax’s sales growth is negative 10% for the ongoing quarter and 270.6% for the next.
Volume
Today’s last reported volume for Novavax is 7526340 which is 2.13% above its average volume of 7369100.
Moving Average
Novavax’s worth is way below its 50-day moving average of $6.57 and way under its 200-day moving average of $7.50.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Novavax’s EBITDA is 0.24.
More news about Novavax (NVAX).
